pp-198 Solution for infusion
Dossier type
US CTD
Dossier status
Under development
Country of origin
United States
GMP approvals
FDA
Comments
Indication: Neonatal hypoxic-ischaemic encephalopathy (HIE) — neuroprotection at birth asphyxia
Clinical stage: Phase 2
Modality: Small biologic / peptide (first-in-class 15-amino acid cyclic peptide — dual mechanism inhibitor)
Mechanism / Target: First-in-class dual inhibitor of complement pathway activation AND myeloperoxidase (MPO)/neutrophil extracellular trap (NET) formation; the bifunctional peptide simultaneously suppresses two key inflammatory cascades responsible for neonatal brain injury
Route / form: IV infusion
Differentiation: First-in-class dual complement/MPO-NET inhibitor with a single peptide molecule; novel two-in-one anti-inflammatory mechanism;
Manufacturer #39337
US-based clinical-stage biopharmaceutical company developing a first-in-class systemic injectable Rx biologic that targets multiple upstream inflammatory drivers. Lead program is in mid-stage clinical development for a serious acute condition with high unmet need.
None